Cochrane · systematic review · CD002030
Photodynamic therapy for neovascular age‐related macular degeneration
Wormald, R, Evans, JR, Smeeth, LL, et al. · Cochrane Database of Systematic Reviews · 2007 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 4 · 80%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Photodynamic therapy with verteporfin compared to photodynamic therapy with 5% dextrose in water for neovascular age‐related macular degeneration
Population: patients with neovascular age‐related macular degeneration
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose | RR 0.8 [0.73, 0.88] | 4 studies · 1381 participants | High |
Loss of 6 or more lines (30 or more letters) visual acuity ETDRS chart Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose | RR 0.66 [0.53, 0.83] | 4 studies · 1381 participants | High |
Gain of 3 or more lines (15 or more letters) Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose | RR 2.23 [1.19, 4.19] | 3 studies · 941 participants | High |
Adverse effects: acute severe visual acuity decrease Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose | RR 3.75 [0.87, 16.12] | 3 studies · 1075 participants | Moderate Downgraded: imprecision |
Adverse effects: infusion‐related back pain Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose | RR 9.93 [2.82, 35.02] | 4 studies · 1439 participants | High |